ABSTRACT
The efficacy of acetyldinaline [4-acetylamino-N-(2'-aminophenyl)-benzamide] for eradication of minimal residual disease (MRD), which is left after bone marrow transplantation, and the risk of a bone marrow graft being jeopardized by this treatment was studied in the Brown Norway rat acute myelocytic leukemia model (BNML). To mimic the clinical situation, MRD induction treatment was given to rats showing clinical signs of leukemia and consisted of 80 mg/kg cyclophosphamide and 7.0 Gy X-rays total body irradiation resulting in a 6-8 log leukemic cell kill leaving 10-1000 leukemic cells in the animals. Treatment was completed with a syngeneic bone marrow transplant. A high dose level (HD) treatment of 23.7 mg acetyldinaline/kg per day and a low dose level (LD) treatment of 11.85 mg/kg per day, each given orally for five consecutive days, were compared. The increase in the survival time, the cure rate, and the toxic death rate were evaluated. One 5-day course of LD treatment, started at a time interval of 10, 17, or 24 days following MRD induction, resulted in 44%, 11% or 0% cures. With two 5-day courses of LD treatment, 89%, 22%, or 0% cures were achieved. With LD treatment, maximally an 8 log leukemic cell kill was obtained and no toxicity-related deaths were observed (only less than a 1 log kill of normal hemopoietic stem cells). In contrast, a single course of HD treatment resulted in 56% of the rats (10/18) dying from intestinal tract toxicity, while from the remaining eight rats at risk for relapse, three (37%) showed a very late relapse and five were cured (63%). It was evident that the leukemic cell load at the start of the acetyldinaline treatment determined the probability of relapse. An important finding was that acetyldinaline did not interfere with bone marrow regeneration. The highly curative potential of acetyldinaline treatment in the BNML model during the phase of MRD warrants the introduction of this compound in clinical phase I/II studies.
Subject(s)
Antineoplastic Agents/therapeutic use , Leukemia, Myeloid, Acute/drug therapy , Phenylenediamines/therapeutic use , Animals , Antineoplastic Agents/administration & dosage , Benzamides , Bone Marrow Transplantation , Disease Models, Animal , Drug Screening Assays, Antitumor , Leukemia, Myeloid, Acute/therapy , Male , Phenylenediamines/administration & dosage , Rats , Rats, Inbred BN , RecurrenceABSTRACT
Diabetes mellitus and cardiovascular disorders are both common disorders, and it could be anticipated that they coexist in many patients. Diltiazem (DZ) is widely used alone or in combination with propranolol (PROP) for the treatment of hypertension and ischemic heart disease. These drugs could interfere with carbohydrate metabolism and impair glucose tolerance. The purpose of this study was to investigate the effect of oral administration of DZ, PROP (100 and 25 mg kg-1, respectively) and their combination on fasting serum glucose and insulin levels in normal and diabetic Wistar rats. Diabetes was induced by an intraperitoneal (i.p.) injection of streptozotocin (60 mg kg-1). In normal animals, serum glucose was significantly increased after DZ, PROP and DZ/PROP treatment compared to the initial values. In diabetic rats, serum glucose was significantly increased after PROP and DZ/PROP treatments, while it was slightly increased after diltiazem treatment compared to the initial values. In normal animals, plasma cAMP is significantly decreased in all treatment groups compared to the control value, while in the plasma of diabetic rats, cAMP was significantly decreased after PROP and DZ/PROP treatments when compared to the control value. Serum potassium of normal rats decreased after the diltiazem and DZ/PROP treatments, and they tend to increase slightly after PROP treatment. Serum potassium of diabetic rats was increased significantly after PROP and DZ/PROP treatments compared to the initial values. Body weight is decreased significantly in all treatment groups in normal rats while this significant decrease was observed only after DZ/PROP treatment in diabetic rats. This investigation suggests that diltiazem alone has no worsening effects on the glycemic control in diabetic rats.(ABSTRACT TRUNCATED AT 250 WORDS)
Subject(s)
Blood Glucose/metabolism , Diabetes Mellitus, Experimental/metabolism , Diltiazem/pharmacology , Propranolol/pharmacology , Animals , Body Weight/drug effects , Calcium/blood , Calcium/metabolism , Cyclic AMP/blood , Cyclic AMP/metabolism , Drug Interactions , Glucose Tolerance Test , Insulin/blood , Male , Organ Size/drug effects , Potassium/blood , Potassium/metabolism , Rats , Rats, WistarABSTRACT
Benzyl chloride (BCL) is extensively used in industry for the manufacture of dyes, perfumes, and pharmaceutical products. A previous study from this laboratory revealed the presence of liver steatosis of the microvesicular type and central focal inflammation in rats following the inhalation of BCL. This study was conducted to investigate the hepatotoxicity of intravenous (iv) BCL in rat. BCL (250, 25, and 0 micrograms/kg) was administered (iv) to rats, and serum enzyme tests were used to evaluate hepatic injury. After 10 min from BCL administration, serum glutamic-pyruvic transaminase and lactic dehydrogenase activities were significantly increased compared to the control group, while the values returned to normal within 1 h from the administration of BCL. Also, ornithine carbamyltransferase enzyme activity was significantly increased and reached a maximum as early as 0.5 h from the administration of BCL. Hepatic excretory function was investigated by the clearance of bromosulfophthalein (BSP) after 0.5 and 24 h from the administration of BCL. The clearance of BSP in both treatments was significantly slower compared to control group throughout the 24 h studied. Furthermore, BCL significantly decreased liver and blood glutathione values. This study revealed that BCL has the potential to cause hepatomalfunction.